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To the Editor:
The majority of bone marrow transplants (BMT) are con-
ditioned with reduced intensity protocols, greatly expanding
the range of eligible patients and disease indications [1].
However, protocol diversity now presents a major obstacle
to evidence-based assessments of the effectiveness of BMT
in pathways of care. Protocol diversity also has a potential
negative impact on the credibility of BMT as a therapeutic
option in the view of other healthcare professionals, trial
investigators, and healthcare purchasers. Here, we report the
findings of a British Society of Bone Marrow Transplan-
tation and Anthony Nolan Protocol Harmonization Initiative
that evaluated the diversity of reduced intensity BMT pro-
tocols in use at all 25 UK transplant centers. The aim of the
survey was to identify opportunities to achieve a more
harmonized approach in order to facilitate future registry
based and prospective clinical studies.
Reduced intensity conditioning (RIC) protocols for BMT
have proliferated and diversified enormously, since the late
1990s [1]. A strong impetus to innovate has resulted in
empirical adoption of many different protocols unsupported
by trial evidence. While fludarabine has become almost
universally established as a useful agent, it has been com-
bined with a wide range and dosing schedules of che-
motherapy and radiotherapy. Variation in T-cell depletion
strategies has added further diversity. Alemtuzumab,
effective for the transplantation of unrelated donors, is now
frequently incorporated into RIC regimens the UK [2–4]
while anti-thymocyte globulin is favored by others [5]. In
common with many other elements, there has been no
randomized comparison of these approaches. The selection
of particular protocols for specific indications and patient
groups remains highly idiosyncratic.
Centers providing allogeneic transplantation were
recruited between January 2015 and January 2017 through
direct email or telephone contact with BMT program
directors, quality managers, or clinical specialist nurses. All
25 UK allogeneic centers responded with details of their
protocols. Twenty-four centers reported allograft activity
using sibling and unrelated donors. One center reported
sibling transplantation only. Drug dose and scheduling of
the major protocol groups were compiled by EBMT center
number in a graphical format. Simpson’s diversity index D
was calculated according to the formula D= 1 − (Σ(n/N)2),
where n= number of identical protocols and N= total
number of protocols.
Centers provided protocols in use for hematological
malignancy including myelofibrosis and for aplastic ane-
mia. Five major protocol groups were identified: fludarabine
and melphalan (with or without alemtuzumab); fludarabine
and busulfan with either alemtuzumab or ATG; Carmustine/
lomustine, etoposide, cytarabine, and melphalan (BEAM)
with alemtuzumab; fludarabine and TBI nonmyeloablative
“Seattle” regimens [6] and protocols for aplastic anemia
(Fig. 1a). Fludarabine cyclophosphamide protocols for
indications other than aplastic anemia were only reported in
by three centers and not included. Every center returned at
least one fludarabine-based RIC protocol, the median
number of protocols was 6 ranging from 2 to 9. The primary
goal of the survey was to describe the diversity of protocols
in use, rather than the indication for use of the protocol, the
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donor choice or any other ancillary factors such as the use
of growth factors, and target ciclosporin level. These are
likely to be important variables in outcome but it is
impossible to assess their impact in the face of such pro-
tocol diversification.
Protocols were arranged into related subgroups for ease
of visualization of diversity. Fludarabine melphalan
protocols are shown as an example (Fig. 1b–d). A similar
approach was used to describe variability in the four other
main groups (Figs. S1–S4). A Diversity Index (DI) was
derived using Simpson’s method to give a score between 0
(all protocols different) and 1 (all protocols identical) for
each major group. Increasing DI therefore reflects greater
harmonization (Fig. 1e). The most harmonized protocol was
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Fig. 1 Survey of protocol
diversity. a The range of
protocols across 25 allograft
centers. Dark shading denotes
that the use of protocol was
reported. F fludarabine, M
melphalan, B busulfan, Cy
cyclophosphamide, BEAM
BCNU/carmustine, etoposide,
ara-C, melphalan, TBI 2 Gy total
body irradiation, A
Alemtuzumab, ATG anti-
thymocyte globulin, MTX
methotrexate, MF myelofibrosis.
“Kroger” based on Kroger et al.
[12]; “Seattle”: based on
Niederweiser et al. [6]; asterisk
denotes the sibling only center.
BEAM protocols include
BEAM, LEAM (lomustine),
LACE and F-BEAM. ATG
includes Fresenius and Genzyme
products. Cy ATG includes one
Cy Alem protocol. Numbers
following alemtuzumab denote
total dose in milligrams. b
Fludarabine melphalan and
alemtuzumab 30 mg protocols.
Drug, dosing, and timing of
administration (day pre
transplant) are defined in the
vertical axis with a separate
column for each center reporting
a protocol. Identical protocols
are grouped together across the
horizontal axis. Flu fludarabine,
Mel melphalan, Alem
alemtuzumab. The dosing
indicated is mg/m2 for
fludarabine and melphalan and
total milligram dose for
alemtuzumab. Trial protocols
for UKALL14 and FIGARO
are indicated. c Fludarabine
melphalan alemtuzumab
50–60 mg protocols. d
Fludarabine melphalan
alemtuzumab 90–100 mg
protocols. e Each major protocol
group was subjected to Diversity
Index (DI) calculation using
Simpson’s Diversity Index and
arranged in decreasing order
(least to most diverse).
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cyclophophosphamide and ATG for sibling donors in aplastic
anemia (0.4). Fludarabine busulfan ATG, in which every
protocol was unique, scored the lowest (0.07). A detailed
description of the factors underlying variability of each pro-
tocol group is given in the Supplementary information.
The purpose of this study was to describe the extent of
protocol variation, based on self-reported use of protocols
by transplant centers, in order to identify potential routes to
harmonization or at least a reduction of protocol diversity.
Almost every parameter of a conditioning protocol was
subject to variation without obvious rationale. In specific
instances, erroneous reasoning was advanced, for example,
transplant centers were divided almost equally about giving
melphalan on day −2 or day −1 with some expressing
apparently groundless concerns over residual effects on the
graft when delivered at day −1. Melphalan has a very short
terminal half-life of 17–75 min and proven safety in patients
with end-stage renal failure, with no objective reason not to
deliver the drug 24 h before stem cell infusion [7].
Much of the variation observed was due to the dose and
scheduling of Alemtuzumab and ATG. The depth of T-cell
depletion practised by individual transplant centers reflects
notions of how much GVHD is tolerable or desirable, based
on unquantifiable subjective arguments [8]. Alemtuzumab
has a long in vivo half-life and the timing and fractionation
of dosing is critical in its effect [9]. A commonly used dose
reduction to 60 mg given as two 30 mg doses on day −2
and −1 leads to higher plasma concentrations than the
100 mg dose originally administered in five fractions from
day −9 [10]. It was generally not appreciated that this “end-
loaded” 60 mg schedule is not an effective dose reduction.
Busulfan-containing protocols were highly variable often
due to a wide range of once daily intravenous, QDS intra-
venous, and even oral regimens. There was a tendency to
schedule busulfan early in the regimen that is not well
justified by pharmacokinetic considerations; several pub-
lished studies employ this agent as late as day −2 without
difficulty and with the potential advantage of fewer days of
neutropenia [11]. Access to pharmacy manufacturing at the
weekend remains a determinant of busulfan scheduling in
the UK in more than half of transplant centers surveyed.
Fludarabine busulfan ATG protocols, intended for use in
myelofibrosis, were reported by a number of centers refer-
ring to “Kroger” as a model [12]. However, all 15 were
unique in some way and none reproduced the published
protocol exactly. A significant source of deviation from the
published protocol was the widespread use of Genzyme
rabbit ATG (thymoglobulin) in place of Fresenius ATG.
Finally, a set of consensus protocols was developed.
These represent the smallest number of discrete protocols
that could satisfy the requirements of the majority of
transplant centers. This was arrived at by two rounds of
discussion and feedback from UK transplant center
Directors, following presentation of the initial audit at the
Anthony Nolan Annual Clinical Retreat in 2016 and 2017.
The set of consensus protocols is included in the Supple-
mentary Information for reference.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM,
Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation
in older patients with hematologic malignancies: replacing high-
dose cytotoxic therapy with graft-versus-tumor effects. Blood.
2001;97:3390–400.
2. Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A,
et al. Allogeneic stem-cell transplantation for lymphoproliferative
disorders using BEAM-CAMPATH (+/− fludarabine) con-
ditioning combined with post-transplant donor-lymphocyte infu-
sion. Cytotherapy. 2001;3:203–10.
3. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD,
Verfuerth S, et al. Limiting transplantation-related mortality fol-
lowing unrelated donor stem cell transplantation by using a non-
myeloablative conditioning regimen. Blood. 2002;99:1071–8.
4. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux
S, et al. Reduced-intensity allogeneic hematopoietic stem cell
transplantation for myelodysplastic syndrome and acute myeloid
leukemia with multilineage dysplasia using fludarabine, busul-
phan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:
1616–23.
5. Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M,
Burchardt A, et al. Antithymocyte globulin for the prevention of
graft-versus-host disease after unrelated hematopoietic stem cell
transplantation for acute myeloid leukemia: results from the
multicenter German cooperative study group. Bone Marrow
Transpl. 2005;35:1011–8.
6. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U,
Sandmaier BM, et al. Low-dose total body irradiation (TBI) and
fludarabine followed by hematopoietic cell transplantation (HCT)
from HLA-matched or mismatched unrelated donors and post-
grafting immunosuppression with cyclosporine and mycopheno-
late mofetil (MMF) can induce durable complete chimerism and
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan. . .
sustained remissions in patients with hematological diseases.
Blood. 2003;101:1620–9.
7. Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis
D, et al. High-dose melphalan and stem cell transplantation in
patients on dialysis due to immunoglobulin light-chain amyloi-
dosis and monoclonal immunoglobulin deposition disease. Biol
Blood Marrow Transplant. 2018;24:127–32.
8. Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S,
et al. Impact of alemtuzumab scheduling on graft-versus-host
disease after unrelated donor fludarabine and melphalan allografts.
Biol Blood Marrow Transplant. 2017;23:805–12.
9. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C,
Goldstone AH, et al. Pharmacokinetics of alemtuzumab used for
in vivo and in vitro T-cell depletion in allogeneic transplantations:
relevance for early adoptive immunotherapy and infectious com-
plications. Blood. 2003;102:404–6.
10. Jardine L, Publicover A, Bigley V, Hale G, Pearce K, Dickinson
A, et al. A comparative study of reduced dose alemtuzumab in
matched unrelated donor and related donor reduced intensity
transplants. Br J Haematol. 2015;168:874–81.
11. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C,
Yerushalmi R, et al. Comparison between two fludarabine-based
reduced-intensity conditioning regimens before allogeneic hema-
topoietic stem-cell transplantation: fludarabine/melphalan is
associated with higher incidence of acute graft-versus-host disease
and non-relapse mortality and lower incidence of relapse than
fludarabine/busulfan. Leukemia. 2007;21:2109–16.
12. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N,
et al. Pilot study of reduced-intensity conditioning followed by
allogeneic stem cell transplantation from related and unrelated
donors in patients with myelofibrosis. Br J Haematol. 2005;
128:690–7.
Affiliations
Chloe Anthias1 ● Jane Apperley2 ● Adrian Bloor3 ● Jennifer Byrne 4 ● Matthew Collin 5 ● Charles Crawley6 ●
Charles Craddock7 ● Damian Finnegan8 ● Maria Gilleece 9 ● John Gribben 10 ● Ann Hunter11 ● Hannah Hunter12 ●
Mickey Koh13 ● Stephen Mackinnon14 ● Ram Malladi7 ● David Marks15 ● Grant McQuaker16 ● Manos Nikolousis17 ●
Kim Orchard18 ● Jiri Pavlu2 ● Andrew Peniket19 ● Mike Potter1 ● Victoria Potter20 ● Stephen Robinson15 ●
Nigel Russell4 ● Rahuman Salim21 ● John Snowden 22 ● Kirsty Thomson14 ● Eleni Tholouli23 ● Keith Wilson24
1 The Royal Marsden NHS Foundation Trust, London, UK
2 Hammersmith Hospital, Imperial College Healthcare NHS Trust,
London, UK
3 The Christie NHS Foundation Trust, Manchester, UK
4 Nottingham City Hospital, Nottingham University Hospitals NHS
Trust, Nottingham, UK
5 Northern Center for Cancer Care, Newcastle upon Tyne Hospitals
NHS Foundation Trust, Newcastle upon Tyne, UK
6 Addenbrooke’s Hospital, Cambridge University Hospitals NHS
Foundation Trust, Cambridge, UK
7 Queen Elizabeth Hospital, University Hospitals Birmingham NHS
Foundation Trust, Birmingham, UK
8 Belfast City Hospital, Belfast, UK
9 St James’s University Hospital, The Leeds Teaching Hospitals
NHS Trust, Leeds, UK
10 Barts Cancer Center, Barts Health NHS Trust, Leeds, UK
11 Leicester Royal Infirmary, University Hospitals of Leicester NHS
Trust, Leeds, UK
12 Derriford Hospital, University Hospitals Plymouth NHS Trust,
Plymouth, UK
13 St George’s University Hospitals NHS Foundation Trust,
London, UK
14 University College London Hospitals NHS Foundation Trust,
London, UK
15 Bristol Haematology and Oncology Center, University Hospitals
Bristol NHS Foundation Trust, Bristol, UK
16 The Beatson West of Scotland Cancer Center, Glasgow, UK
17 Heartlands Hospital, University Hospitals Birmingham NHS
Foundation Trust, Birmingham, UK
18 University Hospital Southampton, NHS Foundation Trust,
Southampton, UK
19 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
20 King’s College Hospital NHS Foundation Trust, London, UK
21 Royal Liverpool and Broadgreen University Hospital NHS Trust,
Liverpool, UK
22 Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, UK
23 Manchester Royal Infirmary, Manchester University NHS
Foundation Trust, Leeds, UK
24 University Hospital of Wales, Cardiff and Vale University Health
Board, Cardiff, UK
C. Anthias et al.
